CPT1A and gastric cancer: CPT1B was upregulated in oxaliplatin-treated GC cells (HGC27 and MGC803), and the CPT1 inhibitor perhexiline and oxaliplatin inhibited tumor xenograft progression in a subcutaneous xenograft BALB/c nude mouse model of HGC27 cells, suggesting that CPT1-mediated fatty acid translocation and further fatty acid oxidation may be associated with oxaliplatin CPT1C expression was found to be substantially linked to poor DFS and OS in GC patients.